Differentially expressed proteins of MCF-7 human breast cancer cells affected by Zilongjin, a complementary Chinese herbal medicine

Proteomics - Clinical Applications

Volumn 4, Issue 5, 2010, Pages 550-559

  Tian, Zhi Hua ^a   Li, Zheng Fu ^a   Zhou, Shao Bo ^b   Liang, Yun Yan ^a   He, Da Cheng ^c   Wang, Dai Shu ^a  

^a China   (China)

^b UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^c BEIJING NORMAL UNIVERSITY   (China)

Author keywords

Differentially expressed proteins; MCF 7 cells; Zilongjin

Indexed keywords

CYTOKERATIN 18; HERBACEOUS AGENT; MACROPHAGE CAPPING PROTEIN; TROPOMODULIN 3; TUMOR PROTEIN; TUMOR PROTEIN D52; UBIQUITIN CONJUGATING ENZYME E2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; NEOPLASM PROTEINS; PROTEOMICS; UP-REGULATION;

EUKARYOTA;

EID: 77953757262     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900092     Document Type: Article

References (34)

1. Zhang, X., Liu, S. J., Liang, Y.Y., Liu, X. D. et al., Clinical study on treatment of moderate and advanced stage cancers by Bailong Tablets combined with chemotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi 1998, 18, 24-25.
2. Su, J. H., Wu, L. Y., Zhou, R. Y., The clinical observation for detoxication and synergistic effect of Zilongjin on lung cancer in mid-half advanced stages. Chin. J. Clin. Oncol. 2002, 29, 593-594.
3. Li, Q., Wu, Q., Li, H. K., Cui, Y. L. et al., Effect of Zilongjin on immunologic function of patients with hepatocarcinoma in perioperative stage. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005, 25, 163-164.
4. Wang, D. S., Shi, X. D., Liang, Y. Y., Liu, J., Regulation of Chinese medicine Bailong and Hexamethylene bisacetamide on cyclin dependent kinase inhibitor P16 genes in human cancer cell. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001, 21, 763-766.
5. Li, X. S., Liang, Y. Y.,Wang, D. S., Xie, X. et al., In vitro effect of Zilongjin on prostate cancer cell line LNCaP. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004, 24, 621-624.
6. Li, B. Y., Liang, Y. Y., Wang, D. S., Ding, Q. X. et al., Regulative effects of bailong and Hexamethylene bisacetamide on growth and phenotype of human gastric cancer cells in cell cycle. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001, 21, 354-358.
7. Gu, S. Q., Liang, Y. Y., Fan, L. R., Li, B. Y. et al., Regulation of traditional Chinese medicine formulae Bailong on cAMP-PKA and DAG-PKC signal pathways of human gastric cancer cells. Zhongguo Zhong Xi Yi Jie He Za Zhi 1997, 17, 404-407.
8. Liu, J., Liu, H. T., Liang, Y. Y.,Wang, D. S., Effect of compound Chinese medicine Bailong on the expression of tumor suppressor genes and relationship with prekallikrein activatior signal pathway in human gastric carcinoma BGC82-3 cell line. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999, 19, 613-615.
9. Jiang, N., Huo, H. R., Li, L. F., Zhou, J. et al., Changes in hypothalamus proteins levels in febrile rat after administration of Cinnamic Aldehyde. J. Pharmacol. Clin. Chin. Mater. Med. 2003, 19, 11-13.
10. Xie, W. G., Shao, N. S., Ma, X. C., Ding, Q. X. et al., Study on serum proteome of rat endotoxemia treated by figwort root. Zhong guo Zhong Yao Za Zhi 2004, 29, 877-882.
11. Stewart, B., Kleihues, P., World Cancer Report. IARC Press: Lyon 2003, pp. 160-163, 188-193.
12. Parkin, D. M., Bray, F., Ferlay, J., Pisani, P., Global cancer statistics, 2002. CA. Cancer J. Clin. 2005, 55, 74-108.
13. Guo, F., Nian, H., Zhang, H., Tang, Y. et al., Proteomic analysis of the transition from quiescent to proliferating stages in rat liver hepatectomy model. Proteomics 2006, 6, 3075-3086.
14. -ΔΔCT method. Methods 2001, 25, 402-408.
15. Valásek, L., Nielsen, K. H., Zhang, F., Fekete, C. A. et al., Interactions of eukaryotic translation initiation factor 3 (eIF3) subunit NIP1/c with eIF1 and eIF5 promote preinitiation complex assembly and regulate start codon selection. Mol. Cell Biol. 2004, 24, 9437-9455.
16. Ahlemann,M., Zeidler, R., Lang, S.,Mack, B. et al., Carcinomaassociated eIF3I overexpression facilitates mTOR-dependent growth transformation. Mol. Carcinog. 2006, 45, 957-967.
17. Zhang, L., Pan, X., Hershey, J. W. B., Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast. Cells J. Biol. Chem. 2007, 282, 5790-5800.
18. Spataro, V., Norbury, C., Harris, A. L., The ubiquitin-proteasome pathway in cancer. Br. J. Cancer 1998, 77, 448-455.
19. Yew P. R., Ubiquitin-mediated proteolysis of vertebrate G1-and S-phase regulators. J. Cell Physiol. 2001, 187, 1-10.
20. Bischoff, F. R., Krebber, H., Smirnova, E., Dong, W. et al., Coactivation of RanGTPase and inhibition of GTP dissociation by Ran-GTP binding protein RanBP1. EMBO J. 1995, 14, 705-715.
21. Silverman-Gavrila, R. V., Wilde, A., Ran is required before metaphase for spindle assembly and chromosome alignment and after metaphase for chromosome segregation and spindlemidbody organization.Mol. Biol. Cell. 2006, 17, 2069-2080.
22. Gregorio, C. C., Weber, A., Bondad, M., Pennise, C. R., Fowler, V. M., Requirement of pointed-end capping by tropomodulin to maintain actin filament length in embryonic chick cardiac myocytes. Nature 1995, 377, 83-86.
23. Pollard, T. D., Blanchoin, L., Mullins, R. D., Actin dynamics. J. Cell Sci. 2001, 114, 3-4.
24. Dos Remedios, C. G., Chhabra, D., Kekic, M., Dedova, I. V. et al., Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol. Rev. 2003, 83, 433-473.
25. Shestakova, E. A., Wyckoff, J., Jones, J., Singer, R. H. et al., Correlation of X-actin messenger RNA localization with metastatic potential in rat adenocarcinoma cell lines. Cancer Res. 1999, 59, 1202-1205.
26. Byrne, J. A., Mattei, M. G., Basset, P., Definition of the tumor protein D52 (TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52). Genomics 1996, 35, 523-532.
27. Proux-Gillardeaux, V., Galli, T., Callebaut, I., Mikhailik, A. et al., D53 is a novel endosomal SNARE-binding protein that enhances interaction of syntaxin 1 with the synaptobrevin 2 complex in vitro. J. Biochem. 2003, 370, 213-221.
28. Boutros, R., Fanayan, S., Jennifer, A., Byrne, J. A., The tumor protein D52 family: many pieces, many puzzles. Biochem. Biophys. Res. Commun. 2004, 325, 1115-1121.
29. Boutros, R., Byrne, J. A., D53 (TPD52L1) is a cell cycleregulated protein maximally expressed at the G2-M transition in breast cancer cells. Exp. Cell Res. 2005, 310, 152-165.
30. Buhler, H., Schaller, G., Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol. Cancer Res. 2005, 3, 365-371.
31. Schaller, G., Fuchs, I., Pritze, W., Ebert, A. et al., Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin. Cancer Res. 1996, 2, 1879-1885.
32. Tetu, B., Bnisson, J., Landry, J., Huot, J., Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study. Breast Cancer Res. Treat. 1995, 36, 93-97.
33. Vargas-Roig, L.M., Fanelli,M. A., Lopez, L. A., Gago, F. E. et al., Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect. Prev. 1997, 21, 441-451.
34. Doak, S. H., Jenkins, G. J., Parry, E. M., Griffiths, A. P. et al., Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression. Mutat. Res. 2004, 547, 133-144.